Pramipexole protects against H2O2-induced PC12 cell death

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 372, Issue 4, 2006, Pages 257-266

  Fujita, Yoshiko ^a   Izawa, Yuki ^a   Ali, Nermin ^a   Kanematsu, Yasuhisa ^a   Tsuchiya, Koichiro ^a   Hamano, Shuichi ^a   Tamaki, Toshiaki ^a   Yoshizumi, Masanori ^b  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; MAP kinase; Oxidative stress; Parkinson's disease; PC12 cell; Pramipexole

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; [6 (4' AMINO)PHENOXY 3H XANTHEN 3 ON 9 YL]BENZOIC ACID; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BENZOIC ACID DERIVATIVE; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE INHIBITOR; DOMPERIDONE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; FLUORESCENT DYE; HYDROGEN PEROXIDE; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PRAMIPEXOLE; REACTIVE OXYGEN METABOLITE; SPIPERONE; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SULPIRIDE; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT; BENZOTHIAZOLE DERIVATIVE; CASP3 PROTEIN, RAT; CASPASE; CYTOCHROME C; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROPROTECTIVE AGENT; PRAMIPEXOL; THIAZOLE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ASSAY; CELL DEATH; CELL PROTECTION; CELL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME RELEASE; NONHUMAN; OXIDATIVE STRESS; RAT; ANIMAL; CELL SURVIVAL; METABOLISM;

ANIMALS; ANTIPARKINSON AGENTS; APOPTOSIS; BENZOTHIAZOLES; CASPASE 3; CASPASES; CELL DEATH; CELL SURVIVAL; CYTOCHROMES C; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; HYDROGEN PEROXIDE; L-LACTATE DEHYDROGENASE; MITOGEN-ACTIVATED PROTEIN KINASES; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PC12 CELLS; RATS; THIAZOLES;

EID: 31144433876     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-005-0025-2     Document Type: Article

References (51)

1. Abramova NA, Cassarino DS, Khan SM, Painter TW and Bennett JP, Jr. (2002) Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J Neurosci Res 67:494-500
2. Ali N, Yoshizumi M, Tsuchiya K, Kyaw M, Fujita Y, Izawa Y, Abe S, Kanematsu Y, Kagami S and Tamaki T (2004) Ebselen inhibits p38 mitogen-activated protein kinasemediated endothelial cell death by hydrogen peroxide. Eur J Pharmacol 485:127-135
3. Andersen JK (2004) Oxidative stress in neurodegeneration: cause or consequence? Nat Med 10 Suppl:S18-S25
4. Bennett JP, Jr. and Piercey MF (1999) Pramipexole - a new dopamine agonist for the treatment of Parkinson's disease. J Neurol Sci 163:25-31
5. Callsen D and Brune B (1999) Role of mitogen-activated protein kinases in S-nitrosoglutathione-induced macrophage apoptosis. Biochemistry 38:2279-2286
6. Cassarino DS, Fall CP, Smith TS and Bennett JP, Jr. (1998) Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitocnondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem 71:295-301
7. Chan PH (1996) Role of oxidants in ischemic brain damage. Stroke 27:1124-1129
8. Choi HJ, Lee SY, Cho Y and Hwang O (2004) JNK activation by tetrahydrobiopterin: implication for Parkinson's disease. J Neurosci Res 75:715-721
9. Cohen GM (1997) Caspases: the executioners of apoptosis. Biochem J 326 (Pt 1):1-16
10. Earnshaw WC, Martins LM and Kaufmann SH (1999) Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68:383-424
11. Fahn S and Cohen G (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 32:804-812
12. Ferger B, Teismann P and Mierau J (2000) The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study. Brain Res 883:216-223
13. Ferrer I, Blanco R, Carmona M, Puig B, Barrachina M, Gomez C and Ambrosio S (2001) Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies. J Neural Transm 108:1383-1396
14. Green DR and Reed JC (1998) Mitochondria and apoptosis. Science 281:1309-1312
15. Gu M, Iravani MM, Cooper JM, King D, Jenner P and Schapira AH (2004) Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem 91:1075-1081
16. Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59:1609-1623
17. Halliwell B and Aruoma OI (1991) DNA damage by oxygen-derived species. Its mechanism and measurement in mammalian systems. FEBS Lett 281:9-19
18. Ham J, Eilers A, Whitfield J, Neame SJ and Shah B (2000) c-Jun and the transcriptional control of neuronal apoptosis. Biochem Pharmacol 60:1015-1021
19. Harada J and Sugimoto M (1999) An inhibitor of p38 and JNK MAP kinases prevents activation of caspase and apoptosis of cultured cerebellar granule neurons. Jpn J Pharmacol 79:369-378
20. Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A, Turmel H, Srinivasan A, Ruberg M, Evan GI, Agid Y and Hirsch EC (2000) Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A 97:2875-2880
21. Hou RC, Huang HM, Tzen JT and Jeng KC (2003) Protective effects of sesamin and sesamolin on hypoxic neuronal and PC12 cells. J Neurosci Res 74:123-133
22. Jacobson MD (1996) Reactive oxygen species and programmed cell death. Trends Biochem Sci 21:83-86
23. Jenner P and Olanow CW (1998) Understanding cell death in Parkinson's disease. Ann Neurol 44:S72-S84
24. Jeon BS, Kholodilov NG, Oo TF, Kim SY, Tomaselli KJ, Srinivasan A, Stefanis L and Burke RE (1999) Activation of caspase-3 in developmental models of programmed cell death in neurons of the substantia nigra. J Neurochem 73:322-333
25. Kakimura J, Kitamura Y, Takata K, Kohno Y, Nomura Y and Taniguchi T (2001) Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur J Pharmacol 417:59-67
26. Kitamura Y, Kosaka T, Kakimura JI, Matsuoka Y, Kohno Y, Nomura Y and Taniguchi T (1998) Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol Pharmacol 54:1046-1054
27. Koyama AH, Akari H, Adachi A, Goshima F and Nishiyama Y (1998) Induction of apoptosis in HEp-2 cells by infection with herpes simplex virus type 2. Arch Virol 143:2435-2441
28. Kulich SM and Chu CT (2001) Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. J Neurochem 77:1058-1066
29. Kyriakis JM and Avruch J (1996) Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem 271:24313-24316
30. Lange KW (1998) Clinical pharmacology of dopamine agonists in Parkinson's disease. Drugs Aging 13:381-389
31. Le WD, Jankovic J, Xie W and Appel SH (2000) Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm 107:1165-1173
32. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479-489
33. Matsura T, Kai M, Fujii Y, Ito H and Yamada K (1999) Hydrogen peroxide-induced apoptosis in HL-60 cells requires caspase-3 activation. Free Radic Res 30:73-83
34. Nair VD, Olanow CW and Sealfon SC (2003) Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J 373:25-32
35. Olanow CW, Jenner P and Brooks D (1998) Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 44:S167-S174
36. Ramirez AD, Wong SK and Menniti FS (2003) Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms. Eur J Pharmacol 475:29-35
37. Rascol O (2000) The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease. J Neurol 247 Suppl 2:II51-57
38. Sawada H, Ibi M, Kihara T, Urushitani M, Akaike A, Kimura J and Shimohama S (1998) Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann Neurol 44:110-119
39. Schapira AH (2002) Neuroprotection and dopamine agonists. Neurology 58:S9-S18
40. Setsukinai K, Urano Y, Kakinuma K, Majima HJ and Nagano T (2003) Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species. J Biol Chem 278:3170-3175
41. Song BJ, Soh Y, Bae M, Pie J, Wan J and Jeong K (2001) Apoptosis of PC12 cells by 4-hydroxy-2-nonenal is mediated through selective activation of the c-Jun N-terminal protein kinase pathway. Chem Biol Interact 130-132:943-954
42. Tabner BJ, Turnbull S, El-Agnaf OM and Allsop D (2002) Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic Biol Med 32:1076-1083
43. Tibbles LA and Woodgett JR (1999) The stress-activated protein kinase pathways. Cell Mol Life Sci 55:1230-1254
44. Traver S, Salthun-Lassalle B, Marien M, Hirsch EC, Colpaert F and Michel PP (2005) The neurotransmitter noradrenaline rescues septal cholinergic neurons in culture from degeneration caused by low-level oxidative stress. Mol Pharmacol 67:1882-1891
45. Troadec JD, Marien M, Darios F, Hartmann A, Ruberg M, Colpaert F and Michel PP (2001) Noradrenaline provides long-term protection to dopaminergic neurons by reducing oxidative stress. J Neurochem 79:200-210
46. Tschopp J, Thome M, Hofmann K and Meinl E (1998) The fight of viruses against apoptosis. Curr Opin Genet Dev 8:82-87
47. Widmann C, Gibson S, Jarpe MB and Johnson GL (1999) Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 79:143-180
48. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326-1331
49. Yoshizumi M, Kogame T, Suzaki Y, Fujita Y, Kyaw M, Kirima K, Ishizawa K, Tsuchiya K, Kagami S and Tamaki T (2002a) Ebselen attenuates oxidative stress-induced apoptosis via the inhibition of the c-Jun N-terminal kinase and activator protein-1 signalling pathway in PC12 cells. Br J Pharmacol 136:1023-1032
50. Yoshizumi M, Tsuchiya K, Suzaki Y, Kirima K, Kyaw M, Moon JH, Terao J and Tamaki T (2002b) Quercetin glucuronide prevents VSMC hypertrophy by angiotensin II via the inhibition of JNK and AP-1 signaling pathway. Biochem Biophys Res Commun 293:1458-1465
51. Zou L, Jankovic J, Rowe DB, Xie W, Appel SH and Le W (1999) Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci 64:1275-1285